Henry Schein, Inc. (HSIC) is a Medical - Distribution company in the Healthcare sector, currently trading at $77.20. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of HSIC = $147.54 (+91.1% from the current price, the stock appears undervalued). Analyst consensus target is HSIC = $90 (+16.8% upside).
Valuation: HSIC trades at a trailing Price-to-Earnings (P/E) of 22.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.14.
Financials: revenue is $13.2B, +1.4%/yr average growth. Net income is $398M, growing at -9%/yr. Net profit margin is 3% (thin). Gross margin is 29.1% (-1.2 pp trend).
Balance sheet: total debt is $3.7B against $3.2B equity (Debt-to-Equity (D/E) ratio 1.14, moderate). Current ratio is 1.38 (adequate). Debt-to-assets is 32.9%. Total assets: $11.2B.
Analyst outlook: 14 / 32 analysts rate HSIC as buy (44%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 30/100 (Fail), Past 100/100 (Pass), Health 50/100 (Partial), Moat 53/100 (Partial), Future 46/100 (Partial), Income 30/100 (Fail).
